Institute of Cell Biology, Zhejiang University, Hangzhou 310058, China.
Anat Rec (Hoboken). 2013 Feb;296(2):273-8. doi: 10.1002/ar.22628. Epub 2012 Nov 23.
Although several studies detected the BRCA1 germ-line mutations in Chinese women with familial breast cancer, most of them did not employ conventional full gene sequencing, especially in eastern China. In addition, the clinicopathological features of BRCA1-associated breast cancer in Chinese women were not well investigated. In this study, we screened the complete coding regions and exon-intron boundaries of BRCA1 by polymerase chain reaction (PCR)-sequencing assay. Immunohistochemistry analyses were performed on tumor samples to detect the expression of estrogen receptor (ER), progesterone receptor (PR), P53, and human epidermal growth factor receptor-2 (HER-2). Breast cancer patients having one or more affected relatives referred from the Zhejiang Cancer Hospital, eastern China during 2008-2011 were selected for the study. A total of 62 familial breast cancer patients received the BRCA1 germ-line mutation screening. Five deleterious mutations were detected in this cohort. The mutation rate was 11.3% (7/62). We found two novel mutations (3414delC and 5,280 C > T) and two recurrent mutations (5,273 G > A and 5589del8). BRCA1 mutation tumors tended to be negative for ER, PR, and HER-2, and exhibited high histological grade compared with tumors without BRCA1 mutations. Our study suggests that recurrent mutations may exist in eastern Chinese women with familial breast cancer and PCR-sequencing assay is a useful tool to screen these mutations. It also suggests that BRCA1-associated breast cancers in Chinese women exhibit an aggressive phenotype.
虽然几项研究在中国有家族性乳腺癌的女性中检测到 BRCA1 种系突变,但大多数研究并未采用常规的全基因测序方法,尤其是在中国东部。此外,BRCA1 相关乳腺癌在中国女性中的临床病理特征尚未得到充分研究。在这项研究中,我们通过聚合酶链反应(PCR)-测序分析筛选 BRCA1 的完整编码区和外显子-内含子边界。对肿瘤样本进行免疫组织化学分析,以检测雌激素受体(ER)、孕激素受体(PR)、P53 和人表皮生长因子受体-2(HER-2)的表达。本研究选取 2008-2011 年期间来自中国东部浙江肿瘤医院的一位或多位受影响亲属的乳腺癌患者进行 BRCA1 种系突变筛查。共有 62 例家族性乳腺癌患者接受了 BRCA1 种系突变筛查。在该队列中检测到 5 个有害突变。突变率为 11.3%(7/62)。我们发现了两个新突变(3414delC 和 5,280 C > T)和两个复发性突变(5,273 G > A 和 5589del8)。BRCA1 突变肿瘤倾向于 ER、PR 和 HER-2 阴性,与无 BRCA1 突变的肿瘤相比,具有较高的组织学分级。我们的研究表明,中国东部有家族性乳腺癌的女性可能存在复发性突变,PCR 测序分析是筛选这些突变的有用工具。这也表明中国女性的 BRCA1 相关乳腺癌表现出侵袭性表型。